Concho Resources heavyweight WuXi AppTec continues to see significant momentum following its impressive earnings report. On the morning of August 5, WuXi AppTec A-shares surged in volume, initially extending gains by over 6% before settling at a 4.6% increase as of 10:15 AM. Trading volume exceeded 12 billion yuan, surpassing the previous day's total and ranking among the top five in A-share turnover. The largest medical ETF in the market, HuaBao Medical ETF (512170), also rose with its intraday price hitting a new high in this round of rebound. Data shows that WuXi AppTec is the top holding of the HuaBao Medical ETF, with a latest position weight of 12.69%. The underlying index of the HuaBao Medical ETF covers eight leading Concho Resources stocks, collectively accounting for nearly 30% of the weight.

On the evening of August 3, WuXi AppTec released its semi-annual report, which exceeded market expectations: revenue for the first half of the year reached 28.897 billion yuan, up 38.93% year-on-year; net profit attributable to the parent company historically surpassed 10 billion yuan for the first time in the first half, reaching 11.08 billion yuan, a 29.43% increase year-on-year; Q2 single-quarter revenue of 16.5 billion yuan set a new record. Additionally, the company raised its full-year 2026 guidance, projecting total revenue to increase from 51.3-53 billion yuan to 58.5-60.5 billion yuan, with year-on-year growth for continuing operations revised from 18%-22% to 35%-39%.

Notably, several overseas multinational corporations, including Johnson & Johnson, Sanofi, Bristol-Myers Squibb, Novartis, and Roche, have recently disclosed positive interim reports and raised their 2026 full-year guidance. Orders, revenues, and profitability in the CDMO and CRO sectors continue to improve. Northeast Securities believes that domestic and international biopharmaceutical financing is steadily recovering, with domestic innovative drug financing surging. Policy support for innovative drug development is multifaceted, and the Concho Resources sector may be entering a new upward cycle.

To efficiently participate in Concho Resources trading, consider two key tools: HuaBao Medical ETF (512170): the largest medical and healthcare ETF in the market, focusing on medical devices (including brain-computer interfaces) and medical services (with nearly 30% Concho Resources exposure), also covering AI healthcare concepts. Off-market fund: 012323. HuaBao Hong Kong Stock Connect Medical ETF (159137): heavily weighted in innovative drug chain, with 48% Concho Resources and 20% innovative drugs, also covering AI healthcare, medical devices (including brain-computer interfaces), and other scarce leaders in the field. Its underlying assets are Hong Kong stocks, offering high elasticity and T+0 trading. Off-market fund: 026922.

Data sourced from the Shanghai and Shenzhen Stock Exchanges, CSI Index Company, etc., with weights as of July 31, 2026. Institutional views: Northeast Securities dated July 27, 2026, in "Northeast Medical and Health Weekly Report: Continuing to See Innovative Drugs and Devices as the Long-Term Main Line, AI Healthcare Has Entered a Value Realization Window." Industrial Securities dated August 3, 2026, in "Industrial Securities Pharmaceutical Industry August 2026 Investment Monthly Report." Note: The ETFs mentioned in the article do not charge sales service fees. Fund rates are detailed in each fund's legal documents. Risk warning: The index constituents shown are for display purposes only. Stock descriptions do not constitute any form of investment advice, nor do they represent the holdings or trading movements of any fund under the fund manager. The composition of the underlying index constituents is adjusted in accordance with the index compilation rules. The fund manager assesses the risk level of the HuaBao Hong Kong Stock Connect Medical ETF and its off-market fund as R4-Medium to High Risk, suitable for aggressive (C4) and above investors, while the HuaBao Medical ETF is assessed as R3-Medium Risk, suitable for balanced (C3) and above investors. Any information appearing in this article (including but not limited to stocks, comments, forecasts, charts, indicators, theories, and any form of expression) is for reference only. Investors must be responsible for any investment decisions they make independently. Additionally, any views, analyses, and forecasts in this article do not constitute investment advice to readers, nor are we responsible for any direct or indirect losses arising from the use of this content. Fund investment carries risks. The past performance of a fund does not represent its future performance. The performance of other funds managed by the fund manager does not constitute a guarantee of the fund's performance. Fund investment requires caution. MACD golden cross signals are forming, these stocks are performing well!